#United States #San Diego #biopharmaceuticals #Cancer Research #IDEAYA Biosciences

IDEAYA Biosciences to Present at AACR 2026

IDEAYA Biosciences, a notable name in precision oncology, has unveiled its plan to present important research at the upcoming American Association for Cancer Research (AACR) Annual Meeting in April 2026. With three poster presentations highlighting their advanced clinical stage pipeline, the company aims to share transformative findings in cancer treatment.

Overview of the Event

The AACR Annual Meeting is set to take place from April 17 to April 22 in sunny San Diego, California. It represents a significant platform for the latest advancements in cancer research and treatment methodologies. IDEAYA will focus on exhibiting preclinical data related to three promising therapies: IDE034, IDE574, and IDE892.

Insights into the Pipeline Programs

1. IDE034: This innovative therapy is a bispecific antibody-drug conjugate (ADC) designed to target PTK7 and B7-H3, two key proteins involved in tumor progression. The data from this program exhibits enhanced antitumor activity compared to mono-specific ADCs, showcasing the potential for a novel treatment option in various solid tumors.

2. IDE574: Known for its dual inhibitory action on lysine acetyltransferase (KAT) 6 and 7, IDE574 disrupts tumor lineage and combats drug tolerance. Its targeted approach may lead to significant breakthroughs in cancer care, particularly for patients with specific biomarkers.

3. IDE892: This therapy operates as a highly selective inhibitor of PRMT5, optimized for treating cancers that exhibit specific genetic alterations. It also demonstrates cooperative interaction with another compound, IDE397, highlighting its potential effectiveness in combination therapies.

Goals of the Presentations

Michael White, Ph.D., Chief Scientific Officer of IDEAYA Biosciences, expressed enthusiasm for the opportunity to showcase their work at the AACR meeting. The company is keen to illustrate how their research aligns with their focus on TOP1 ADCs and mechanisms of DNA damage repair, synthetic lethality, and epigenetic modulation.

Their overarching mission is to facilitate the development of first-in-class and best-in-class therapeutic profiles capable of delivering robust efficacy. They aim to provide rational combinations that could foster deeper and more durable patient responses.

Presentation Details

The following are key details of the presentations:

• - Poster Number 232: IDE034 will be presented by Munoz Delgado, D. et al., scheduled for April 19, 2026, from 2:00 PM to 5:00 PM PDT.
• - Poster Number 4483: IDE574's insights will be shared by Gupta, M. et al., on April 21, 2026, between 9:00 AM and 12:00 PM PDT.
• - Poster Number 4505: Rao, A. et al. will discuss IDE892 during the same session as IDE574 on April 21, 2026.

Future Directions

Following the AACR meeting, IDEAYA plans to make the poster presentations available on their corporate website. This commitment signifies their transparency and eagerness to engage with the scientific community.

IDEAYA Biosciences remains steadfast in its goal to uncover and develop innovative therapies aligned with the genetic intricacies of cancer. Their work in synthetic lethality and ADCs sets a promising horizon for oncology treatments, where tailored approaches promise better outcomes for patients battling cancer.

In summary, IDEAYA's presentations at AACR 2026 are not merely about showcasing data but symbolize a significant step towards redefining cancer therapies through precision medicine. As they continue to navigate the complexities of oncology, their discoveries may pave the way for transformative care to improve the lives of countless patients worldwide.